News & Media
Intelligent Bio Solutions announces the pricing of an underwritten public offering of units for gross proceeds of approximately $4.0 million.
International certification adds to Quality Management Systems credentials for the medical device industry and supports expansion plans into North America and Asia Pacific regions.
The Workplace Health & Safety Show is Australia’s only workplace health and safety event, with thousands of health and safety decision makers from multiple sectors attending the live, interactive learning experience showcasing cutting-edge technology, ideas, and practices in workplace safety.
New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin next stage of transfer to manufacture.
Intelligent Bio Solutions Inc. today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.
Since the Company’s entry into the Australian market with its Intelligent Fingerprinting Drug Screening System, the dedicated efforts of the sales force have resulted in the addition of 8 new customers across the Mining, Aviation, Construction, Manufacturing, and Agriculture industries.
Palletways is using the fingerprint drug test, which uses sweat to determine if employees have recently ingested illicit drugs that could affect their fitness to work, as part of its employee induction process.
IBS Inc. has signed a distribution agreement for its Intelligent Fingerprinting Drug Screening System with Chile-based company TSCOM SPA, increasing the product’s availability across South America.
IBS Inc. has received guidance from the U.S. Food and Drug Administration regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge.
Intelligent Bio Solutions has received a second progress payment of USD $1.43 million as part of a scientific grant awarded to the Company in 2021 for USD $4.7 million.
Intelligent Bio Solutions has announced that management will be participating in the LD Micro Invitational XIII in Los Angeles, June 6-8, 2023.
Lab-testing pathway to expand capabilities of proprietary drug test screening to detect potent opioid fentanyl and fentanyl-adulterated street drugs.